Cybin Inc. to Present at H.C. Wainwright Global Investment Conference

Cybin Inc., a clinical-stage neuropsychiatry company, announced that Chief Business Officer George Tziras will participate in a fireside chat at the H.C. Wainwright 27th Annual Global Investment Conference on September 8, 2025, at 11:00 a.m. ET. The company, which trades on both the NYSE American and Cboe CA under the symbol CYBN, is developing next-generation treatment options for mental health conditions.

Cybin is committed to revolutionizing mental healthcare through the development of innovative treatments that address the large unmet need for people suffering from mental health disorders. The company's approach focuses on creating novel drugs that provide effective and durable results for patients, potentially transforming the mental health treatment landscape. With promising class-leading data, Cybin's research pipeline includes investigational compounds focused on 5-HT receptors.

The company's lead development programs include CYB003, a proprietary deuterated psilocin analog currently in Phase 3 studies for the adjunctive treatment of major depressive disorder. This treatment has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration, indicating its potential to address serious conditions where current therapies are inadequate. Additionally, Cybin is developing CYB004, a proprietary deuterated N, N-dimethyltryptamine molecule in Phase 2 study for generalized anxiety disorder.

Founded in 2019, Cybin has established operations across multiple countries including Canada, the United States, the United Kingdom, and Ireland. The company's participation in the H.C. Wainwright conference provides an opportunity to showcase its progress and future plans to the investment community. Investors can access the latest news and updates relating to CYBN through the company's newsroom at https://ibn.fm/CYBN.

The presentation at this prestigious investment conference underscores the growing importance of neuropsychiatry and mental health treatment development in the healthcare sector. As mental health awareness continues to increase globally, companies like Cybin are positioned to potentially make significant contributions to treatment options that could benefit millions of people worldwide. The conference participation also highlights the increasing investor interest in innovative mental health solutions and the pharmaceutical sector's shift toward addressing previously underserved medical needs.